Detalles de la búsqueda
1.
Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial.
Blood;
143(14): 1355-1364, 2024 Apr 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38127586
2.
Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies.
Blood;
137(16): 2231-2242, 2021 04 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-33512413
3.
Emicizumab dose up-titration in case of suboptimal bleeding control in people with haemophilia A.
Haemophilia;
29(1): 90-99, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36271487
4.
Health-related quality of life and health status in adolescent and adult people with haemophilia A without factor VIII inhibitors-A non-interventional study.
Haemophilia;
27(3): 398-407, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-33576546
5.
The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies.
Haemophilia;
27(5): 854-865, 2021 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-34171159
6.
Determining meaningful health-related quality-of-life improvement in persons with haemophilia A using the Haemophilia Quality of Life Questionnaire for Adults (Haem-A-QoL).
Haemophilia;
26(6): 1019-1030, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-33084166
7.
Outcomes in children with hemophilia A with inhibitors: Results from a noninterventional study.
Pediatr Blood Cancer;
67(10): e28474, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32776489
8.
Bleeding and safety outcomes in persons with haemophilia A without inhibitors: Results from a prospective non-interventional study in a real-world setting.
Haemophilia;
25(2): 213-220, 2019 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-30724422
9.
Health-related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non-interventional study (NIS).
Haemophilia;
25(3): 382-391, 2019 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-31016855
10.
Bleeding events and safety outcomes in persons with haemophilia A with inhibitors: A prospective, multi-centre, non-interventional study.
Haemophilia;
24(6): 921-929, 2018 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-30295389
11.
Patient preference for emicizumab versus prior factor therapy in people with haemophilia A: Results from the HAVEN 3 and HAVEN 4 studies.
Haemophilia;
27(6): e772-e775, 2021 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-34623725
12.
HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer.
Gastric Cancer;
18(3): 476-84, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25038874
13.
Long-term outcomes with emicizumab in hemophilia A without inhibitors: results from the HAVEN 3 and 4 studies.
Res Pract Thromb Haemost;
8(2): 102364, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38559572
14.
Pharmacokinetics and coagulation biomarkers in children and adults with hemophilia A receiving emicizumab prophylaxis every 1, 2, or 4 weeks.
Res Pract Thromb Haemost;
8(1): 102306, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38282901
15.
Emicizumab use in females with moderate or mild hemophilia A without factor VIII inhibitors who warrant prophylaxis.
Res Pract Thromb Haemost;
7(8): 102239, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-38193069
16.
Efficacy of emicizumab is maintained throughout dosing intervals for bleed prophylaxis.
Res Pract Thromb Haemost;
7(2): 100077, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36908770
17.
Corrigendum to 'Efficacy of emicizumab is maintained throughout dosing intervals for bleed prophylaxis' [Research and Practice in Thrombosis and Haemostasis, Volume 7, Issue 2, February 2023, 100077].
Res Pract Thromb Haemost;
7(4): 100191, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-37538504
18.
Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study.
Lancet Haematol;
10(3): e168-e177, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36716761
19.
Untreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1-3.
Res Pract Thromb Haemost;
6(6): e12782, 2022 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-36171959
20.
Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies.
Blood Adv;
6(24): 6140-6150, 2022 12 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-35939785